News

Oil and gas producer Kosmos Energy (NYSE:KOS) will be announcing earnings results this Tuesday before market hours. Here’s what you need to know.

Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting results this Tuesday before the bell. Here’s what investors should know.

Moby summary of Vertex Pharmaceuticals Incorporated's Q1 2026 earnings call

Moby summary of ThredUp Inc.'s Q1 2026 earnings call

Moby summary of Ichor Holdings, Ltd.'s Q1 2026 earnings call

Moby summary of Fabrinet's Q3 2026 earnings call

Moby summary of Firefly Aerospace Inc.'s Q1 2026 earnings call

Moby summary of Evolus, Inc.'s Q1 2026 earnings call

Moby summary of ON Semiconductor Corporation's Q1 2026 earnings call

Moby summary of Duolingo, Inc.'s Q1 2026 earnings call

Moby summary of Adeia Inc.'s Q1 2026 earnings call

Moby summary of Pinterest, Inc.'s Q1 2026 earnings call

Vertex Pharmaceuticals (NASDAQ:VRTX) reported first-quarter 2026 total revenue of $2.99 billion, up 8% year over year, as growth in its cystic fibrosis (CF) franchise and contributions from newer launches helped drive results. CEO and President Dr. Reshma Kewalramani said the company is “off to a te

The headline numbers for Grab (GRAB) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Oil prices fell as wary markets monitored a fragile US-Iran ceasefire in the wait for the latest rush of earnings.

Major gauges traded close to flat as investors adjusted to news that ships in the Strait of Hormuz had been struck with missiles.

Joining me on today's call are Alexander C. Karp, chief executive officer; Shyam Sankar, chief technology officer; David A. Glazer, chief financial officer; and Ryan Taylor, chief revenue officer and chief legal. Ryan Taylor: The last three months have been some of the most exciting in the history of Palantir Technologies Inc. as we have watched the whole world begin to see the incredible promise of operational AI as well as the risks and perils of being beholden to models alone.

Palantir Technologies (NASDAQ:PLTR) reported first-quarter 2026 results that executives said reflected accelerating demand for the company’s Artificial Intelligence Platform (AIP), highlighting record growth rates, expanding profitability metrics, and raised full-year guidance. Q1 growth accelerate

onsemi (NASDAQ:ON) executives struck an optimistic tone on the company’s first quarter 2026 earnings call, pointing to improving demand signals, accelerating AI data center growth, and continued gross margin expansion as evidence the company has moved past the low point of the current cycle. Presid

Firefly Aerospace (NASDAQ:FLY) reported record first-quarter 2026 revenue as management pointed to accelerating demand across lunar missions, national security software, and launch services. The company posted first-quarter revenue of $80.9 million for the period ended March 31, up from $57.7 millio

Duolingo (NASDAQ:DUOL) executives used the company’s first-quarter 2026 earnings call to highlight product execution focused on improving instruction—particularly speaking practice—while reiterating full-year financial targets that reflect what CFO Gillian Munson described as a “key strategic invest

R. Jeffrey Bailly: Thank you, Ron, and thank you to everyone joining the call. UFP had a strong second quarter. Revenue from our two largest customers, Intuitive Surgical and Stryker, grew 10% and 567%, respectively.

Please refer to the Investors section of our website for important information including our earnings press release and investor presentation, which include our GAAP to non-GAAP reconciliation as well as additional details of our revenue breakdown. In addition, today's discussion will contain forward-looking statements about the future financial performance of the company.

Parag Agarwal: Good afternoon, and thank you for joining ON Semiconductor Corporation’s first quarter results conference call. Important factors that can affect our business, including factors that could cause actual results to differ materially from our forward-looking statements, are described in our most recent Form 10-K, Form 10-Q, and other filings with the Securities and Exchange Commission and in our earnings release for the first quarter.

Both Uber and Lyft are expected to report their next set of quarterly results soon. But are analysts' revisions bearish or bullish?

Paul will share general observations regarding the quarter, then Keith will provide further details on our financial results and guidance. First, today’s discussion contains forward-looking statements that are predictions, projections, or other statements about future events which are based on management’s current expectations and beliefs, and therefore are subject to risks, uncertainties, and changes in circumstances. For more information on the risks and uncertainties that could cause our actual results to differ materially from what we discuss today, please refer to the Risk Factors section in our SEC filings, including our Annual Report on Form 10-K and our Quarterly Report on Form 10-Q. Please note that the company does not intend to update or alter these forward-looking statements to reflect events or circumstances arising after this call.

Evolus (NASDAQ:EOLS) reported first-quarter results that management said reflected a stronger operating model following cost structure changes implemented last year, while reiterating its full-year 2026 outlook for double-digit revenue growth and adjusted EBITDA profitability. First-quarter results

Ichor (NASDAQ:ICHR) reported first-quarter 2026 results that landed at the upper end of management’s expectations, driven by a sharp sequential increase in demand and what executives described as improving operating leverage early in a multi-year growth cycle. First-quarter results show sequential

Vertex Pharmaceuticals Incorporated is off to a terrific start in 2026, which we see as a year defined by execution. Q1 revenue growth was strong across the portfolio as we reach more patients with more products and delivered total product revenue of $2.99 billion, reflecting 8% growth year over year. Another highlight in Q1 was that products from the new disease areas, namely KASJEVY and GERNAVICS, drove approximately 25% of total product revenue growth.

Adeia (NASDAQ:ADEA) reported first-quarter 2026 results driven by new license agreements and continued expansion beyond its legacy pay TV business, while also disclosing that President and CEO Paul Davis plans to step down later this year. Quarterly results and deal activity Davis said the company